ReviewFrontiers in medicine2025
Advances in ocular aging: combining deep learning, imaging, and liquid biopsy biomarkers.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AI-driven strategies for advancing corneal cell therapy: a promising frontier.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ageing is a significant risk factor for a wide range of human diseases. Yet, its direct relationship with ocular ageing as a marker for overall age-related diseases and mortality still needs to be explored. Non-invasive and minimally invasive methods, including biomarkers detected through ocular imaging or liquid biopsies from the aqueous humour or vitreous body, provide a promising avenue for assessing ocular ageing. These approaches are particularly valuable given the eye's limited regenerative capacity, where tissue damage can result in irreversible harm. In recent years, artificial intelligence (AI), particularly deep learning, has revolutionized medical research, offering novel perspectives on the ageing process. This review highlights how integrating deep learning with advanced imaging and liquid biopsy biomarkers has become a transformative approach to understanding ocular ageing and its implications for systemic health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.